Loading clinical trials...
Loading clinical trials...
The objective of this study is to determine the effectiveness of PEG-Intron 1.5 ug/kg/wk plus REBETOL (ribavirin) 800-1400 mg/day in adults with chronic hepatitis C with moderate to severe liver fibro...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Merck Sharp & Dohme LLC
NCT02417740 · Cystic Fibrosis, Immunologic Deficiency Syndrome, and more
NCT03587831 · NASH - Nonalcoholic Steatohepatitis
NCT07572383 · Interstitial Lung Disease, Pulmonary Fibrosis
NCT07281781 · Myelofibrosis, Myelofibrosis; Anemia
NCT07069725 · Liver Fibrosis, Hepatic Cirrhosis
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions